Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3
The California biotech will use the cash infusion to support its pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead candidate that takes aim at a common form of epilepsy.
The California biotech will use the cash infusion to support its pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead candidate that takes aim at a common form of epilepsy.
